Phase 1b Study of LY3295668 erbumine Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

NOT ENROLLING
Protocol # :
19-246
Conditions
Small Cell Lung Cancer
Phase
I
Disease Sites
Lung
Principal Investigator
Sands, Jacob
Site Investigator
Farago, Anna, F.
Rangachari, Deepa
Site Research Nurses
Aspinwall, Sheridan
Burke, Millicent
Drevers, Dawn
Kelley, Elaine
Kuberski, Heather, D.
Stober, Lisa, L.
Sullivan, Molly, O'Brien
Wanat, Alexandra

Trial Description

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine
in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Eligibility Requirements

Inclusion Criteria:

- Have histological or cytological evidence of a diagnosis of platinum sensitive small
cell lung cancer that is extensive stage.

- Have adequate organ function.

- Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
scale.

- Have discontinued previous treatments for cancer.

- Are able to swallow capsules.

Exclusion Criteria:

- Currently enrolled in a clinical study.

- Have a serious concomitant systemic disorder.

- Have a symptomatic human immunodeficiency virus infection or symptomatic
activated/reactivated hepatitis B or C.

- Have a significant cardiac condition.

- Have previously received an aurora kinase inhibitor.

19-246